Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor.
Hall
Harald A
HA
Division of Rheumatology, Roger Williams Medical Center, Providence, Rhode Island 02908, USA. Halexhall@yahoo.com
Zimmermann
Bernard
B
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001706:Biopsy; D003882:Dermatomyositis / Q000139:chemically induced* / Q000473:pathology; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D018482:Muscle, Skeletal / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept